-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective : Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in people over 50 years of ag.
Objectives Objective : Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in people over 50 years of ag.
Methods : In this double-blind, multicenter Phase 2/3 clinical trial, the research team randomly assigned 36 patients with new-onset polymyalgia rheumatica from three centers to receive subcutaneous injection of anti-IL-6 tocilizumab ( 162 mg per week ) or placebo for 16 weeks ( 1:1 ratio.
Methods In this double-blind, multicenter Phase 2/3 clinical trial, the research team randomly assigned 36 patients with new-onset polymyalgia rheumatica from three centers to receive subcutaneous injections of anti-IL-6 tocilizumab (each 162 mg per week ) or placebo for 16 weeks ( 1:1 ratio.
Results From November 20 , 2017 , to October 28 , 2019 , 39 patients were screened for eligibility; 19 patients received tocilizumab and 17 patients received placeb.
Conclusions In patients with new-onset polymyalgia rheumatica who received rapid glucocorticoid tapering, tocilizumab was superior to placebo for sustained glucocorticoid-free remission, time to relapse, and cumulative glucocorticoid do.
Source: Bonelli M, Radner H, Kerschbaumer A , et a.
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled tri.
Annals of the Rheumatic Diseases2022;81:838-84 , et al Annals of the Rheumatic Diseasesleave a comment here
